Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CD44 | P16070 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929471 | 0.81 | PDE3B (0.52) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL4303165 | 0.73 | ASIC3 (0.51) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL17259056 | 0.73 | ASIC3 (0.45) | PNMTDRD2DRD3CD44MAOB | |
| SCHEMBL21800282 | 0.72 | ASIC3 (0.69) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL1010536 | 0.71 | IGF1R (0.54) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL30276318 | 0.70 | PARP1 (0.46) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL20929265 | 0.70 | PARP1 (0.43) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL20929543 | 0.69 | HTR6 (0.55) | PNMTADRA2AADRA2BADRA2CHTR6 | |
| SCHEMBL6533890 | 0.69 | HTR6 (0.52) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL26684155 | 0.69 | HTR6 (0.49) | PNMTADRA2AADRA2BADRA2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | PNMT 3051/4885ADRA2A 541/4885ADRA2B 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.